Fort Myers Kidney Care Center is a medicare approved dialysis facility center in Fort Myers, Florida and it has 17 dialysis stations. It is located in Lee county at 14181 S Tamiami Trail #120, Fort Myers, FL, 33912. You can reach out to the office of Fort Myers Kidney Care Center at (239) 415-1062. This dialysis clinic is managed and/or owned by American Renal Associates. Fort Myers Kidney Care Center has the following ownership type - Profit. It was first certified by medicare in December, 2013. The medicare id for this facility is 682542 and it accepts patients under medicare ESRD program.
| Name | Fort Myers Kidney Care Center |
|---|---|
| Location | 14181 S Tamiami Trail #120, Fort Myers, Florida |
| No. of Dialysis Stations | 17 |
| Medicare ID | 682542 |
| Managed By | American Renal Associates |
| Ownership Type | Profit |
| Late Shifts | No |
| 14181 S Tamiami Trail #120, Fort Myers, Florida, 33912 | |
| (239) 415-1062 | |
News Archive
Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.
Levels of CoQ and the presence of insulin resistance were analyzed in a range of experimental laboratory settings, mouse models and samples from humans, as part of an ambitious research collaboration conducted with the University of Sydney, Victor Chang Cardiac Research Institute, Duke University School of Medicine, Garvan Institute of Medical Research, Genentech Inc. and the University of New South Wales.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
› Verified 5 days ago
| NPI Number | 1093154916 |
| Organization Name | Fort Myers Kidney Care Center |
| Doing Business As | Fort Myers Kidney Center Llc |
| Address | 14181 S Tamiami Trl Fort Myers, Florida, 33912 |
| Phone Number | (239) 415-1062 |
News Archive
Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.
Levels of CoQ and the presence of insulin resistance were analyzed in a range of experimental laboratory settings, mouse models and samples from humans, as part of an ambitious research collaboration conducted with the University of Sydney, Victor Chang Cardiac Research Institute, Duke University School of Medicine, Garvan Institute of Medical Research, Genentech Inc. and the University of New South Wales.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 75% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 12% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 13% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 73% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 6% | 14% |
News Archive
Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.
Levels of CoQ and the presence of insulin resistance were analyzed in a range of experimental laboratory settings, mouse models and samples from humans, as part of an ambitious research collaboration conducted with the University of Sydney, Victor Chang Cardiac Research Institute, Duke University School of Medicine, Garvan Institute of Medical Research, Genentech Inc. and the University of New South Wales.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 64% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 18% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 18% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 68% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 29% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 3% | 12% |
News Archive
Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.
Levels of CoQ and the presence of insulin resistance were analyzed in a range of experimental laboratory settings, mouse models and samples from humans, as part of an ambitious research collaboration conducted with the University of Sydney, Victor Chang Cardiac Research Institute, Duke University School of Medicine, Garvan Institute of Medical Research, Genentech Inc. and the University of New South Wales.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 89% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 11% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 76% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 19% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 5% | 12% |
News Archive
Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.
Levels of CoQ and the presence of insulin resistance were analyzed in a range of experimental laboratory settings, mouse models and samples from humans, as part of an ambitious research collaboration conducted with the University of Sydney, Victor Chang Cardiac Research Institute, Duke University School of Medicine, Garvan Institute of Medical Research, Genentech Inc. and the University of New South Wales.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
› Verified 5 days ago
| Dialysis patients with Hemoglobin data | 50 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 44 |
News Archive
Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.
Levels of CoQ and the presence of insulin resistance were analyzed in a range of experimental laboratory settings, mouse models and samples from humans, as part of an ambitious research collaboration conducted with the University of Sydney, Victor Chang Cardiac Research Institute, Duke University School of Medicine, Garvan Institute of Medical Research, Genentech Inc. and the University of New South Wales.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
› Verified 5 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 78 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 636 |
| Percentage of adult patients getting regular hemodialysis at the center | 97 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.
Levels of CoQ and the presence of insulin resistance were analyzed in a range of experimental laboratory settings, mouse models and samples from humans, as part of an ambitious research collaboration conducted with the University of Sydney, Victor Chang Cardiac Research Institute, Duke University School of Medicine, Garvan Institute of Medical Research, Genentech Inc. and the University of New South Wales.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
› Verified 5 days ago
| Adult patients getting regular peritoneal dialysis at the center | 21 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 176 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 27 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.
Levels of CoQ and the presence of insulin resistance were analyzed in a range of experimental laboratory settings, mouse models and samples from humans, as part of an ambitious research collaboration conducted with the University of Sydney, Victor Chang Cardiac Research Institute, Duke University School of Medicine, Garvan Institute of Medical Research, Genentech Inc. and the University of New South Wales.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
› Verified 5 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fort Myers Kidney Care Center with elevated calcium levels.
| Patients with hypercalcemia | 100 |
| Hypercalcemia patient months | 834 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 103 |
| Patients with Serumphosphor less than 3.5 mg/dL | 3 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 27 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 37 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 19 |
| Patients with Serumphosphor greater than 7 mg/dL | 13 |
News Archive
Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.
Levels of CoQ and the presence of insulin resistance were analyzed in a range of experimental laboratory settings, mouse models and samples from humans, as part of an ambitious research collaboration conducted with the University of Sydney, Victor Chang Cardiac Research Institute, Duke University School of Medicine, Garvan Institute of Medical Research, Genentech Inc. and the University of New South Wales.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
› Verified 5 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 117 |
| Patient months included in arterial venous fistula and catheter summaries | 588 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 47 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 18 |
News Archive
Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.
Levels of CoQ and the presence of insulin resistance were analyzed in a range of experimental laboratory settings, mouse models and samples from humans, as part of an ambitious research collaboration conducted with the University of Sydney, Victor Chang Cardiac Research Institute, Duke University School of Medicine, Garvan Institute of Medical Research, Genentech Inc. and the University of New South Wales.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
› Verified 5 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 89 |
| Hospitalization Rate in facility | 186.2 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 311.1 |
| Hospitalization Rate: Lower Confidence Limit | 114.6 |
News Archive
Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.
Levels of CoQ and the presence of insulin resistance were analyzed in a range of experimental laboratory settings, mouse models and samples from humans, as part of an ambitious research collaboration conducted with the University of Sydney, Victor Chang Cardiac Research Institute, Duke University School of Medicine, Garvan Institute of Medical Research, Genentech Inc. and the University of New South Wales.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
› Verified 5 days ago
The rate of readmission show you whether patients who were being treated regularly at Fort Myers Kidney Care Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 27.2 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 42 |
| Readmission Rate: Lower Confidence Limit | 15.4 |
News Archive
Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.
Levels of CoQ and the presence of insulin resistance were analyzed in a range of experimental laboratory settings, mouse models and samples from humans, as part of an ambitious research collaboration conducted with the University of Sydney, Victor Chang Cardiac Research Institute, Duke University School of Medicine, Garvan Institute of Medical Research, Genentech Inc. and the University of New South Wales.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
› Verified 5 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Fort Myers Kidney Care Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.86 (As Expected) |
| SIR: Upper Confidence Limit | 3.32 |
| SIR: Lower Confidence Limit | .95 |
News Archive
Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.
Levels of CoQ and the presence of insulin resistance were analyzed in a range of experimental laboratory settings, mouse models and samples from humans, as part of an ambitious research collaboration conducted with the University of Sydney, Victor Chang Cardiac Research Institute, Duke University School of Medicine, Garvan Institute of Medical Research, Genentech Inc. and the University of New South Wales.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
› Verified 5 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Fort Myers Kidney Care Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 65 |
| Transfusion Rate in facility | 77.8 (Worse than Expected) |
| Transfusion Rate: Upper Confidence Limit | 168.1 |
| Transfusion Rate: Lower Confidence Limit | 39.5 |
News Archive
Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.
Levels of CoQ and the presence of insulin resistance were analyzed in a range of experimental laboratory settings, mouse models and samples from humans, as part of an ambitious research collaboration conducted with the University of Sydney, Victor Chang Cardiac Research Institute, Duke University School of Medicine, Garvan Institute of Medical Research, Genentech Inc. and the University of New South Wales.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
› Verified 5 days ago
The rate of mortality show you whether patients who were being treated regularly at Fort Myers Kidney Care Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 257 |
| Mortality Rate in facility | 20.3 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 27.8 |
| Mortality Rate: Lower Confidence Limit | 14.5 |
News Archive
Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.
Levels of CoQ and the presence of insulin resistance were analyzed in a range of experimental laboratory settings, mouse models and samples from humans, as part of an ambitious research collaboration conducted with the University of Sydney, Victor Chang Cardiac Research Institute, Duke University School of Medicine, Garvan Institute of Medical Research, Genentech Inc. and the University of New South Wales.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
› Verified 5 days ago
Fort Myers Dialysis Location: 4220 Executive Circle #38, Fort Myers, Florida, 33916 Phone: (239) 274-3681 |
BMA - South Ft Myers Location: 9400 Gladiolus Dr Ste 200, Fort Myers, Florida, 33908 Phone: (239) 482-6700 |
Fort Myers South Dialysis Location: 8850 Gladiolus Dr, Fort Myers, Florida, 33908 Phone: (239) 415-1661 |
Fort Myers North Dialysis Location: 16101 North Cleveland Ave, Fort Myers, Florida, 33903 Phone: (239) 656-4403 |
Fort Myers Kidney Care Center Location: 14181 S Tamiami Trail #120, Fort Myers, Florida, 33912 Phone: (239) 415-1062 |
News Archive
Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.
Levels of CoQ and the presence of insulin resistance were analyzed in a range of experimental laboratory settings, mouse models and samples from humans, as part of an ambitious research collaboration conducted with the University of Sydney, Victor Chang Cardiac Research Institute, Duke University School of Medicine, Garvan Institute of Medical Research, Genentech Inc. and the University of New South Wales.
Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
› Verified 5 days ago